GenomePrecision

About GenomePrecision

Beijing GenomePrecision Technology Co., Ltd. is a molecular diagnostics company established in June 2015, operating from the Beijing Economic and Technological Development Area. The company was founded by an individual with extensive experience at major domestic and international molecular diagnostics firms, recognized as a leading expert in China. This founding team was driven by the growing demands of precision medicine to create an advanced platform for developing and manufacturing diagnostic equipment and reagents. GenomePrecision operates as an integrated enterprise, handling the research and development, manufacturing, distribution, regulatory registration, and servicing of molecular diagnostic products. The firm's business model is centered on B2B transactions with healthcare providers, hospitals, and research institutions. It generates revenue through the sale of its diagnostic kits and instruments. The company focuses on key clinical areas including hematological oncology, organ and bone marrow transplantation, novel molecular pathology, and tumor immunotherapy detection. To address these markets, the company has built a comprehensive technological foundation encompassing six molecular platforms: real-time fluorescent quantitative PCR, Sanger sequencing, next-generation sequencing, capillary electrophoresis fragment analysis, fluorescent in situ hybridization, and microfluidics. Its product portfolio is extensive, covering leukemia, lymphoma, transplant typing, solid tumor detection, pharmacogenomics, and pathogen detection. One of its subsidiaries, Beijing Search Biotech Co., Ltd., serves as the primary distribution platform and has established a strong market reputation, particularly for its lymphoma clonality assay kits. The company has successfully developed prototypes for a circulating tumor cytometer and a digital PCR instrument, which have shown promising results in clinical trials at several major hospitals.